News about "Orphan Drug Designation "

GSK's Velzatinib Receives Japan Orphan Drug Designation for GIST

GSK's Velzatinib Receives Japan Orphan Drug Designation for GIST

GSK’s investigational KIT inhibitor velzatinib received Orphan Drug Designation in Japan for GIST, supported by Phase 1/1b data and phase 3 trials are underway, with second-line results expected in 2027.

Orphan Drug Designation | 20/11/2026 | By News Bureau

Octant's OCT-980 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa

Octant's OCT-980 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa

Octant is evaluating OCT-980 in a Phase 1b/2 study at US sites, with the aim of developing a potential oral, disease-modifying treatment for RHO-adRP.

Orphan Drug Designation | 29/10/2026 | By News Bureau |  100

Bristol Myers Squibb Reports Positive RYZ101 Phase 3 Results

Bristol Myers Squibb Reports Positive RYZ101 Phase 3 Results

Bristol Myers Squibb reports positive interim results from the Phase 3 ACTION-1 trial of investigational radiopharmaceutical therapy RYZ101 in patients with GEP-NETs.

Orphan Drug Designation | 14/10/2026 | By News Bureau |  138

LEO Pharma to Acquire Global Rights to Tanabe Pharma's Late-Stage Dersimelagon for Rare Skin Diseases

LEO Pharma to Acquire Global Rights to Tanabe Pharma's Late-Stage Dersimelagon for Rare Skin Diseases

LEO Pharma has agreed to acquire worldwide rights to Tanabe Pharma’s oral MC1R agonist dersimelagon for up to USD 435 million in upfront and near-term milestones, strengthening its rare dermatology pipeline for EPP and XLP.

Orphan Drug Designation | 19/08/2026 | By News Bureau |  132

Galibra Neuroscience Earns Dual FDA Designations for Gene Therapy Targeting Rare Neurological Disorder

Galibra Neuroscience Earns Dual FDA Designations for Gene Therapy Targeting Rare Neurological Disorder

Galibra Neuroscience has secured both Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA for its investigational gene therapy for SSADH deficiency, strengthening regulatory support for a potential disease-modifying treatment aimed at addressing the genetic cause of the rare neurological disorder.

Orphan Drug Designation | 06/08/2026 | By News Bureau |  105

TolerogenixX Secures EU Orphan Drug Designation for MIC-Lx in Living-Donor Kidney Transplantation

TolerogenixX Secures EU Orphan Drug Designation for MIC-Lx in Living-Donor Kidney Transplantation

European Commission grants orphan status to Tolerogenix’s personalized cell therapy following EMA recommendation, strengthening its regulatory pathway alongside recent PRIME designation.

Orphan Drug Designation | 14/07/2026 | By News Bureau |  149

Incyte to Acquire Vega Therapeutics, Expanding Hematology Portfolio

Incyte to Acquire Vega Therapeutics, Expanding Hematology Portfolio

Incyte has agreed to acquire Vega Therapeutics, expanding its hematology portfolio into bleeding disorders with the addition of VGA039, a phase 3 investigational monoclonal antibody for von Willebrand disease. The deal includes USD 1.25 billion upfront and up to USD 750 million in additional payments upon achievement of sales milestones.

Orphan Drug Designation | 09/06/2026 | By News Bureau |  248

FDA Grants Priority Review to Sanofi's Venglustat for Type 3 Gaucher Disease

FDA Grants Priority Review to Sanofi's Venglustat for Type 3 Gaucher Disease

Sanofi’s brain-penetrant investigational therapy venglustat has received FDA priority review after phase 3 data demonstrated positive efficacy and safety outcomes in patients with type 3 Gaucher disease.

Orphan Drug Designation | 29/05/2026 | By News Bureau |  197

Lundbeck Secures Orphan Drug Designation in Japan for Asedebart Targeting Rare Endocrine Disorders

Lundbeck Secures Orphan Drug Designation in Japan for Asedebart Targeting Rare Endocrine Disorders

Lundbeck has received orphan drug designation in Japan for asedebart, an investigational ACTH-targeting therapy being developed for congenital adrenal hyperplasia and Cushing’s disease.

Orphan Drug Designation | 18/05/2026 | By News Bureau |  206

SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of SNB-101

SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of SNB-101

SN BioScience initiates first patient dosing in a global phase 1b/2 trial of SNB-101, a nanoparticle anticancer therapy for Small Cell Lung Cancer (SCLC).

Orphan Drug Designation | 16/05/2026 | By News Bureau |  136


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members